Brian Lara

Mr. Brian Lara

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ZWZhongyan Wang
Zhongyan Wang
MSMegan Snyder
Megan Snyder
JKJessica Kenison-White
Jessica Kenison-White
KYKangkang Yang
Kangkang Yang
BLBrian Lara
Brian Lara
DSDavid Sherr
David Sherr
For decades, the aryl hydrocarbon receptor (AHR) was studied for its role in environmental chemical toxicity i.e., as a quirk of nature and a mediator of unintended consequences of human pollution. During that period, it was not certain that the AHR had a “normal” physiological function. However, the ongoing accumulation of data from an ever-expanding variety of studies on cancer, cancer immunity, autoimmunity, organ development, and other areas bears witness to a staggering array of AHR-controlled normal and pathological activities. The objective of this review is to discuss how the AHR has gone from a likely contributor to genotoxic environmental carcinogen-induced cancer to a master regulator of malignant cell progression and cancer aggression. Particular focus is placed on the association between AHR activity and poor cancer outcomes, feedback loops that control chronic AHR activity in cancer, and the role of chronically active AHR in driving cancer cell invasion, migration, cancer stem cell characteristics, and survival.

1 March 2025 in The Journal of Immunology
Verified
Journal Article
Open access
MSMegan Snyder
Megan Snyder
ZWZhongyan Wang
Zhongyan Wang
BLBrian Lara
Brian Lara
JFJocelyn Fimbres
Jocelyn Fimbres
TPTáchira Pichardo
Táchira Pichardo
DSDavid Sherr
David Sherr
While immunotherapy has shown some efficacy in lung adenocarcinoma (LUAD) patients, many respond only partially or not at all. One limitation in improving outcomes is the lack of a complete understanding of immune checkpoint regulation. Here, we investigated a possible link between an environmental chemical receptor implicated in lung cancer and immune regulation, the AhR, a known but counterintuitive mediator of immunosuppression (interferon (IFN)-γ), and regulation of two immune checkpoints (PD-L1 and IDO). AhR gene-edited LUAD cell lines, a syngeneic LUAD mouse model, bulk and scRNA sequencing of LUADs and tumor-infiltrating T cells were used to map out a signaling pathway leading from IFN-γ through the AhR to JAK/STAT, PD-L1, IDO, and tumor-mediated immunosuppression. The data demonstrate that: (1) IFN-γ activation of the JAK/STAT pathway leading to PD-L1 and IDO1 up-regulation is mediated by the AhR in murine and human LUAD cells, (2) AhR-driven IDO1 induction results in the production of Kynurenine (Kyn), an AhR ligand, which likely mediates an AhR→IDO1→Kyn→AhR amplification loop, (3) transplantation of AhR-knockout LUAD cells results in long-term tumor immunity in most recipients. (4) The 23% of AhR-knockout tumors that do grow do so at a much slower pace than controls and exhibit higher densities of CD8+ T cells expressing markers of immunocompetence, increased activity, and increased cell-cell communication. The data definitively link the AhR to IFN-γ-induced JAK/STAT pathway and immune checkpoint-mediated immunosuppression and support the targeting of the AhR in the context of LUAD.

29 May 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BLBrian Lara
Brian Lara
MSMegan Snyder
Megan Snyder
JFJocelyn Fimbres
Jocelyn Fimbres
EYEric Yang
Eric Yang
GSGang Song
Gang Song
DSDavid Sherr
David Sherr
Although immune checkpoint inhibitors show great promise, not all patients respond, and many do not achieve durable responses. Consequently, further investigations into potentially targetable molecules that regulate immune checkpoints are warranted. Previous studies in several cancers demonstrated that interferons produced by tumor-infiltrating leukocytes regulate immunosuppressive PD-L1, PD-L2, and IDO1 through JAK/STAT signaling. Here, we investigated a novel role for an immunosuppressive environmental chemical receptor, previously implicated in smoking-related cancers, in IFN signaling in human lung adenocarcinoma (LUAD) cells. Deletion of the aryl hydrocarbon receptor (AhR) from A549 LUAD cells significantly decreased baseline JAK2, STAT1, STAT3, IRF1 (a JAK/STAT target), PD-L1, PD-L2, and IDO1 expression. IFNγ and IFNα increased the expression of JAK/STAT and immune checkpoint genes and proteins, but these increases were significantly diminished or absent in AhR-knockout cells. The AhR similarly controls IFN-induced, JAK/STAT-driven increases in multiple MHC class I- and class II-related genes. AhR control of type I and type II interferon signaling is mediated through up-regulation of an lncRNA, the IFN-stimulated non-coding RNA 1 (INCR1), and through repression of an RNA-binding protein, heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1), which sequesters JAK/STAT-related and immune checkpoint gene transcripts. The data suggest that the AhR is a key mediator of tumor immunosuppression through regulation of IFN-induced INCR1 and JAK/STAT signaling and, thereby, expression of immune checkpoints. However, that immunosuppression may be tempered by AhR control of MHC expression. Given the multiple roles of JAK/STAT signaling in the immune system, the results also suggest multiple levels at which the AhR may affect tumor immunity.

14 January 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Closed access
TZTiffany Zens
Tiffany Zens
BLBrian Lara
Brian Lara
BOBrielle Ochoa
Brielle Ochoa
RERichard S. Eldredge
Richard S. Eldredge
MGMelinda Gregory
Melinda Gregory
MMMark S. Molitor
Mark S. Molitor

1 May 2023 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MSMegan Snyder
Megan Snyder
BLBrian Lara
Brian Lara
ZWZhongyan Wang
Zhongyan Wang
JFJocelyn Fimbres
Jocelyn Fimbres
MKMohammed Muzamil Khan
Mohammed Muzamil Khan
DSDavid Sherr
David Sherr
Immunotherapy has shown dramatic results in treating cancer, but only a minority of patients benefit. Therefore, there is an unmet medical need to understand the regulation of immune suppression in tumors. We show that the aryl hydrocarbon receptor (AhR) is a central player in regulating immune checkpoints in a mouse model of lung adenocarcinoma (LUAD). Within the murine malignant cell, AhR regulates expression of several genes important to suppressive immune signaling, including PD-L1. We find similar immune-related regulatory mechanisms in human LUAD cells. Notably, the presence of IFNγ boosts the expression of these AhR-regulated suppressive genes, suggesting a deleterious role for IFNγ in LUAD. Transplantation of mouse AhR-knockout CMT167 (CMT167AhR-KO) LUAD cells leads to partial or complete tumor rejection and protection from wild type (WT) LUAD challenge. CMT167AhR-KO tumors that do form have decreased PD-L1 expression and increased T cell infiltration relative to AhR+ control tumors. To identify specific immune cell subsets involved in AhR-related tumor immunity, we employed an imaging mass cytometry (IMC) platform coupled with single cell RNA sequencing of tumor infiltrating CD45+ immune cells. Understanding the phenotypes and spatial orientation of the immune cells interacting with malignant cells will provide evidence of the key immune populations responsible for anti-tumor immunity and thus help pave the way for future therapies and biomarkers relevant to improving treatments for LUAD patients. Find the Cause Consortium Gifts

8 September 2026 in Journal of Surgical Education
Verified
Journal Article
Open access
BLBrian Lara
Brian Lara
EHEvelina Hristova
Evelina Hristova
JLJacie Lemos
Jacie Lemos
ASAayushi Sinha
Aayushi Sinha
SXSteven Xie
Steven Xie
HUHunter J. Underwood
Hunter J. Underwood